Abstract Background: Polymorphisms of different gene have been reported to be associated with cancer including breast cancer. Hospitalization rate for breast cancer has increased over the years in Iran.
Introduction
The numerous endogenous compounds such as estrogen and testosterone are metabolized by a heme-containing enzyme named cytochrome P450 (CYP) [1, 18] . CYP3A subfamily isoforms activate plenty of procarcinogenic polycyclic aromatic hydrocarbon dihydrodiols and metabolize N0-nitrosonornicotine [2] . Polymorphisms of CYP3A gene involved in carcinogen metabolism may affect individual variation in cancer susceptibility [3, 4] and the response to anticancer therapy [5, 6] . Moreover, the CYP3A gene participates in metabolism of many pharmaceutical and recreational drugs; therefore, it has been widely studied in industrialized populations. CYP3A subfamily has two predominant isoforms including CYP3A4 and CYP3A5 enzymes which are expressed in human liver, small intestine jejunum, colon, breast, prostate and pancreas [7] [8] [9] [10] [11] [12] . Both genes have variant alleles all occurring at low frequencies in various ethnic populations [13] . Several SNPs affecting enzyme function have been reported for CYP3A5 gene [14] .
It has been shown that a frequent single nucleotide polymorphism (SNP) of CYP3A5gene, 6896A>G, is associated with CYP3A5 enzyme production and activity [14] . The G>A mutation in intron 3 of the gene leading to a splice defect of the mRNA produces an unstable and nonfunctional protein. The mutated allele and the wild type were named CYP3A5*3(rs776746) and CYP3A5*1, respectively. Only individuals carrying at least one CYP3A5*1 allele can express high levels of CYP3A5 enzyme [15] . CYP3A5*3 allele on the other hand, causes alternative splicing and blocks protein production resulting in either reduced or lost CYP3A5 enzyme activity [8, 16] . CYP3A4 is the major CYP in human hepatic tissue and also expressed in the breast which has an important role in the oxidation of both testosterone (2b-, 6b-, or 15b-hydroxytestosterone) and estrogen (4-and 16a-hydroxylation) [17, 18] . CYP3A4 exhibits a common variant in the 5 0 -flanking region (À290) designated CYP3A4*1B(rs2740574) [19] . In comparison with the wild-type CYP3A4*1A, CYP3A4*1B shows about a 2-fold increase in enzyme activity [18] . CYP3A4*1B leads to an amino acid change resulting in altered protein function and is associated with a variety of cancers including prostate cancer and leukemia in individuals treated with epipodophyllotoxin [20] [21] [22] . Although CYP3A4*1B causes an amino acid change, there is no significant difference between the CYP3A4*1B variant and the wild-type enzymes in the metabolism of testosterone, progesterone, or 7-benzyloxy-4 (trifluoromethyl) coumarin [23] . Not only inter-individual differences in the expression level resulting in tumor development have been connected with CYP3A5 and CYP3A4 polymorphisms, but polymorphism frequencies also differ remarkably among different human populations [24, 25] . Even though these polymorphisms are well characterized in different populations, there is not enough data about the Iranian ethnic group. Furthermore, the association study of these polymorphisms with breast cancer is the first cross-sectional investigation in the world. The aim of the present study is addition valuable data to association studies of CYP3A5 and CYP3A4 with cancer susceptibility. We were going to study the possible association of CYP3A5*3 and CYP3A4*1B SNPs with breast cancer.
Subjects and methods

Subjects
A total of 250 subjects were included in the study consisting of 200 female healthy individuals aged 24-70 years (mean age 44.89 ± 14.30) and 50 unrelated patients suffering from breast cancer aged 20-65 years (mean 41.98 ± 13.91) collected at the Hospitals of Jundishapur University (Ahvaz-southwest of Iran). Ethical approval for this study was obtained from the Ethics Committee of Jundishapur University of Medical Sciences, Ahvaz, Iran.
Genotype analysis
Whole-blood genomic DNA was extracted using the diatom DNA kit (IsoGene, Russia), according to the manufacturer's recommendations. The DNA quantity and quality were determined by Nano-Drop (ND1000; NanoDrop Technologies, Wilmington, DE) and proved to be implemented efficiently as template for PCR. Then, they were stored at À20°C until genotyping. To genotype the A6986G polymorphism in the CYP3A5 gene, polymerase chain reaction (PCR) (Bio-Rad Company -T100ä Thermal Cycler Model) based on the restriction fragment length polymorphism (RFLP) was used as described by Tsuchiya et al. method [26] . The designed primers for CYP3A5 were F: 5 0 -ATGGAGAGTGGCATA GGAGATA-3 0 and R: 5 0 -TGTGGTCCAAACAGGGAAGA AATA-3 0 . Reaction mixtures consisted of 40-50 ng DNA, 1.5 mM master mix, 10 pmol each primer and 1 U Taq polymerase (Qiagen Company), and deionized water to a volume of 25 ll. The PCR for amplifying CYP3A5 was carried out by the following: initial heating at 94°C for 10 min, 40 cycles of 94°C for 30 s, 56°C for 45 s, and 72°C for 30 s and a final extension at 72°C for 5 min. Afterward, the PCR products (130 bp) were digested with restriction enzyme SspI (Fermentas, USA, Catalogue number: ER0771). When the A allele of CYP3A5 was present, it was divided into 107 and 23 fragments and visualized by electrophoresis in 2.5% agarose gel. Unlikely, two-step PCR-RFLP assay was carried out for genotyping of a CYP3A4*1A/B SNP at the promoter region. First, 319-bp PCR product was produced, then secondary PCR using nested primers amplified 168-bp PCR product. As mentioned earlier, PCR reaction mixtures were prepared. The designed primers used for the first PCR reaction were FI: 5 0 -CTGGAGCTGTGGCTTGTTGG-3 0 and RI: 5 0 -CGAAGCAGGGCTGGAGCTGC-3 0 . For amplifying, the PCR conditions were: 95°C for 1 min for an initial denaturation, 40 cycles of 95°C for 45 s, 63°C for 30 s, and 72°C for 30 s and a final extension at 72°C for 5:30 min. Nested primers used for the secondary PCR reaction were FII: 5 0 -GGACAGCCATAGAGACAAGGCCA-3 0 and RII: 5 0 -CAC TCACTGACCTCCTTTGAGTTCA-3 0 . Amplification conditions of the first and second PCR reactions were alike. ScrFI restriction enzyme (Fermentas; USA) digestion of the secondary PCR product results in CYP3A4*1A homozygote's (168-bp fragment) and CYP3A4*1B homozygote's (146-bp and 22-bp fragments) which were shown by 2.5% agarose gel. Several samples were randomly selected and directly sequenced to validate the results of the study (Figs. 1-3 ).
Statistical analysis
The v 2 -test was used to determine if the allele and genotype frequencies of polymorphisms fit the Hardy-Weinberg equilibrium and to compare the obtained results between healthy and affected subjects. Analysis was performed with SPSS software (Statistical Package for the Social Sciences, version 18, SSPS Inc., Chicago, IL, USA), with P-values < 0.05 as the statistical significance. The obtained results were compared between different populations.
Results
In the present study, the allele and genotype frequencies of CYP3A4*1B/*1A and CYP3A5*3/*1 SNPs were determined in 250 subjects from the general population in Ahvaz city (southwest of Iran) including 200 healthy subjects and 50 individuals affected with breast cancer. The genotype frequency of CYP3A4*1A/*1A (A/A) in the both case and control groups was 100%; however, there was no subject with either CYP3A4 * 1A/ * 1B (A/G) orCYP3A4*1B/*1B (G/G) genotype. Since all subjects had the same genotype (A/A), v 2 -test was not performed in order to statistically analyze the genotype frequencies of CYP3A4 gene in the studied population. For CYP3A5 gene, CYP3A5*3/*3mutant homozygote genotype frequency was found to be 99% (n = 198) and 98% (n = 49) in control and patient groups respectively. CYP3A5*1/*1 wild-type genotype, on the other hand, was calculated to be 1% (n = 2) in the control group and 2% (n = 1) in the case group. No CYP3A5*1/*3 heterozygote genotype was detected in both groups. CYP3A5*3 (G) allele frequencies were 99% in healthy individuals and 98% in patients. Moreover, allele frequency of CYP3A5*1 (A) was 1% and 2% in the control group and patient group respectively. The results showed that there was no statistical difference between cases and control and that the CYP3A5 (P-value = 0.561) and CYP3A4 genotypes were not detected among certain groups (Table 1 ).
Discussion
Breast cancer is the most prevalent malignancy among Iranian women [27] . Many genetic-conditions such as sickle cell disease and thalassemias are well known in Iran. Therefore it was assumed that genetic conditions may have a significant impact on breast cancer. The present study was conducted to explore the probable association between cancer-related polymorphisms with the risk of breast cancer among Iranian population. In addition, determination of CYP3A4 and CYP3A5 variant alleles and knowledge about their allelic frequency in Iranian population may lead to individualized drug dosing and improved breast cancer therapeutics.
CYP3A5 genotype and allele frequencies were compared between this study and other studies done on different ethnic populations in the world. Iran is a country which has a large population with different ethnic groups; therefore, the studied population in Ahvaz city (southwest of Iran) can be compared to the population investigated in Shiraz city (south of Iran) [27] . The results of v 2 -test showed that there was no significant difference in the genotype frequencies of CYP3A5 between the two populations (P-value = 0.082). The present study was also compared with other Asian populations, and the comparison showed that CYP3A5 genotype distribution differed from Chinese (P-value < 0.0001) [28, 29] and Japanese populations (P-value < 0.0001) [30] . Genotype frequencies of CYP3A5 were also significantly different from Europeans such as Poland (P-value < 0.0001) [31] , Dutch Caucasian (P-value < 0.0001) [32] , Spain (P-value < 0.0001) [33] , Bosnia, and Herzegovina (P-value < 0.0001) [34] . There were significant differences between this study and the studies on Americans such as American Indians (P-value < 0.0001) [35] and Brazilians (P-value < 0.0001) [36] . Genotype distribution of CYP3A5 was also different from African countries, including Cameroon and South Africa (P-value < 0.0001) [37] ( Table 2 ). So our study indicated that there were noticeable interethnic variations in the frequencies of alleles and genotype for the CYP3A5 polymorphisms among Iranian populations and African, American and Asian populations.
CYP3A4 genotype distribution was also compared between Iranian population and other Asians. The v 2 -test results showed that there was considerable similarity genotype distribution of CYP3A4 gene in the population investigated in Shiraz city. As all subjects in both groups had the (A/A) genotype, no statistical analysis was carried out [27] . In contrast, [37] * N = population size, ** P-values express whether Iranian population is similar to respective populations.
CYP3A4 genotype frequencies were significantly different from Mixed-Ancestry (P-value < 0.0001) [38] and Jordanian populations (P-value < 0.0001) [39] . The result of Chi-square test demonstrated that the genotype distribution of CYP3A4 remarkably differed from European countries, including Poland (P-value = 0.001) [31] and Bosnia and Herzegovina (P-value = 0.001) [34] . There was also a noticeable difference between Iranian and Spanish populations (P-value < 0.0001) [33] . In addition, the genotype frequencies of CYP3A4 were different between this study and American Indian population (P-value = 0.003) [35] . The comparison between CYP3A4 genotype frequencies in this study and the studies on African countries, including Cameroon (P-value < 0.0001) [37] , South Africa (P-value < 0.0001) [37] , Xhosa (P-value < 0.0001) [38] , and Khoisan (P-value < 0.0001) [38] showed there was considerable dissimilarity (Table 3 ). Our study indicated that there were noticeable interethnic variations in the frequencies of alleles and genotype for the CYP3A4 polymorphisms among Iranian populations and European and African populations. The allele and genotype frequencies in CYP3A enzymes may contribute greatly to variation in oral bioavailability and systemic clearance of CYP3A substrates including numerous common therapy drugs and endogenous molecules such as the oxidation of testosterone and the hydroxylation of estrogens [40] . There was a difference in the frequencies of breast cancer in different ethnic groups. Epidemiological evidence reported the relationship of breast cancer frequency (cases per 100,000). The alleles and genotypes frequencies were found significantly different among African, American, Asian and Caucasian populations [40] . The incidence of breast cancer in Iranian women was 22 per 100,000 and the incidence rate of breast cancer in Iran was raised to 93 cases per 100,000 in 2013 [41] . This incidence (in 2007) was less than the incidence rate in African, American, Asian and Caucasian populations (Fig. 4) [40] . Although few studies have investigated a role for CYP3A enzymes activity in breast cancer risk, taken together, previous studies suggest evidence that the major polymorphic variants in CYP3A4 may be associated with steroid metabolism related to breast cancer. CYP3A4*1B in Iranian population is lower than its frequencies in Hispanic population (0.000 in this study). Frequencies of the CYP3A4*1B variant among African Americans is 0.817, among Caucasian is 0.096, among Hisponish is 0.107, among Asian is 0.000 and unknown in Native Americans. The five populations frequencies of CYP3A4*1B are poorly correlated with breast cancer incidence (P-value > 0.1). The results show no association with breast cancer and CYP3A4*1B polymorphism and comparison between Incidence rates of breast cancer in five different ethnic groups, therefore there is no association between breast cancer and frequency of CYP3A4 enzymes activity in most populations. <0.0001 [38] * N = population size. ** P-values express whether Iranian population is similar to respective populations. Ethnic group Figure 4 Comparison between Incidence rates of breast cancer in five different ethnic groups and Iranian population.
Conclusion
In conclusion, the results obtained show that 98% of our sample do not carry a mutant allele. Ethnic and geographic differences may explain discrepancies in the prevalence of CYP3A4 and CYP3A5 polymorphisms. Genotype distribution studies could provide valuable information to help further investigations of association between polymorphisms and several types of cancer. A large database may allow for a more precise estimate of these associations.
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